Original paper
87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7
Abstract
Semaglutide and dulaglutide are glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes (T2D). In SUSTAIN 7, an international, open-label, parallel group trial, adults with inadequately controlled T2D were randomized (1:1:1:1) to once-weekly subcutaneous semaglutide or dulaglutide at low (0.5 vs 0.75 mg) or high (1.0 vs 1.5 mg) doses. Semaglutide provided superior glycemic control and reductions in body weight at both low...
Paper Details
Title
87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7
Published Date
Oct 1, 2019
Journal
Volume
43
Issue
7
Pages
S32 - S32
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History